12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Kynapid vernakalant: Phase III started

Astellas began a double-blind, placebo-controlled, international Phase III ACT 5 trial to evaluate intravenous Kynapid vernakalant in about 450 patients with recent-onset AF with no history of congestive heart failure. Astellas has an SPA from FDA for the trial...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >